Quantifying Spatial Distribution of Ventilation Defects in Multiple Pulmonary Diseases With Hyperpolarized 129Xenon MRI

Hyperpolarized 129Xe MRI assesses lung ventilation, often using the ventilation defect percentage (VDP). Unlike VDP, defect distribution index (DDI) quantifies spatial clustering of defects.BACKGROUNDHyperpolarized 129Xe MRI assesses lung ventilation, often using the ventilation defect percentage (V...

Full description

Saved in:
Bibliographic Details
Published in:Journal of magnetic resonance imaging 2024-10
Main Authors: Bdaiwi, Abdullah S, Willmering, Matthew M, Woods, Jason C, Walkup, Laura L, Cleveland, Zackary I
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hyperpolarized 129Xe MRI assesses lung ventilation, often using the ventilation defect percentage (VDP). Unlike VDP, defect distribution index (DDI) quantifies spatial clustering of defects.BACKGROUNDHyperpolarized 129Xe MRI assesses lung ventilation, often using the ventilation defect percentage (VDP). Unlike VDP, defect distribution index (DDI) quantifies spatial clustering of defects.To quantify spatial distribution of 129Xe ventilation defects using DDI across pulmonary diseases.PURPOSETo quantify spatial distribution of 129Xe ventilation defects using DDI across pulmonary diseases.Retrospective.STUDY TYPERetrospective.Four hundred twenty-one subjects (age = 23.1 ± 17.1, female = 230), comprising healthy controls (N = 60) and subjects with obstructive conditions (asthma [N = 25], bronchiolitis obliterans syndrome [BOS, N = 18], cystic fibrosis [CF, N = 90], lymphangioleiomyomatosis [LAM, N = 50]), restrictive conditions (bleomycin-treated cancer survivors [BLEO, N = 14]; fibrotic lung diseases [FLD, N = 92]), bone marrow transplantation (BMT, N = 53), and bronchopulmonary dysplasia (BPD, N = 19).SUBJECTSFour hundred twenty-one subjects (age = 23.1 ± 17.1, female = 230), comprising healthy controls (N = 60) and subjects with obstructive conditions (asthma [N = 25], bronchiolitis obliterans syndrome [BOS, N = 18], cystic fibrosis [CF, N = 90], lymphangioleiomyomatosis [LAM, N = 50]), restrictive conditions (bleomycin-treated cancer survivors [BLEO, N = 14]; fibrotic lung diseases [FLD, N = 92]), bone marrow transplantation (BMT, N = 53), and bronchopulmonary dysplasia (BPD, N = 19).3 T, two-dimensional multi-slice gradient echo.FIELD STRENGTH/SEQUENCE3 T, two-dimensional multi-slice gradient echo.Whole-lung mean DDI was extracted from DDI maps; correlated with VDP (percent of pixels
ISSN:1522-2586
1522-2586
DOI:10.1002/jmri.29627